Imunon logo

ImunonNASDAQ: IMNN

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

01 March 1999

Next earnings report:

28 March 2025

Last dividends:

N/A

Next dividends:

N/A
$10.44 M
-85%vs. 3y high
19%vs. sector
-vs. 3y high
-vs. sector
-82%vs. 3y high
47%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 15 Nov 2024 23:27:20 GMT
$0.72-$0.01(-0.70%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

IMNN Latest News

Imunon, Inc. (IMNN) Q3 2024 Earnings Call Transcript
seekingalpha.com07 November 2024 Sentiment: NEUTRAL

Imunon, Inc. (NASDAQ:IMNN ) Q3 2024 Earnings Conference Call November 7, 2024 11:00 AM ET Company Participants Kim Golodetz - Alliance Advisors IR Stacy Lindborg - President & Chief Executive Officer David Gaiero - Interim Chief Financial Officer Michael Tardugno - Executive Chairman Conference Call Participants David Bautz - Zacks Kemp Dolliver - Brookline Capital Markets James Molloy - Alliance Global Partners Operator Hello everyone. Good morning.

IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates
globenewswire.com07 November 2024 Sentiment: NEUTRAL

Conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J.

IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com07 October 2024 Sentiment: POSITIVE

LAWRENCEVILLE, N.J., Oct. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) (the “Company”), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of (i) inducement stock options to purchase a total of 60,000 shares of the Company's common stock to one individual hired by Imunon during the fourth quarter of 2024 and (ii) inducement stock options to purchase a total of 50,000 shares of common stock to Susan Eylward, hired by Imunon as General Counsel and Secretary effective October 7, 2024 (collectively, the “Inducement Option Grants”). The Inducement Option Grants were approved in accordance with Nasdaq Listing Rule 5635(c)(4) and were made on October 7, 2024, as a material inducement to each employee's entry into employment with the Company.

UPDATE - IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
globenewswire.com09 September 2024 Sentiment: POSITIVE

September 18 th Event in New York City to Include a Review of the Opportunity for Investigational Therapy IMNN-001 (IL-12) to Treat Advanced Ovarian Cancer and Clinical Development Timeline

IMUNON to Host R&D Day on September 18th
globenewswire.com28 August 2024 Sentiment: POSITIVE

R&D Discussion in New York City to Review IL-12's Potential to Treat Ovarian Cancer Program Features Ovarian Cancer Thought Leaders, OVATION 2 Study Investigators, and Oncology Experts LAWRENCEVILLE, N.J., Aug. 28, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, invites investors to mark their calendars for its R&D Day event to be held at the Harvard Club in New York City on September 18th from 10:00 a.m.

Imunon, Inc. (IMNN) Q2 2024 Earnings Call Transcript
seekingalpha.com14 August 2024 Sentiment: NEUTRAL

Imunon, Inc. (NASDAQ:IMNN ) Q2 2024 Results Conference Call August 14, 2024 11:00 AM ET Company Participants Kim Golodetz - IR Michael Tardugno - Executive Chairman Stacy Lindborg - President and CEO David Gaiero - Interim CFO Conference Call Participants Emily Bodnar - H.C. Wainwright Kemp Dolliver - Brookline Capital Markets David Bautz - Zacks James Molloy - Alliance Global Partners Operator Good morning, everyone.

IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024
globenewswire.com07 August 2024 Sentiment: POSITIVE

LAWRENCEVILLE, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc . (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 11:00 a.m. ET on Wednesday, August 14, 2024 to discuss financial results for the second quarter ended June 30, 2024 and provide an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of first-line, locally advanced-stage ovarian cancer, and on its PlaCCine modality, a proprietary DNA plasmid and a synthetic DNA delivery technology for the expression of pathogen antigens for the development of next-generation vaccines.

IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow
globenewswire.com29 July 2024 Sentiment: POSITIVE

Results to be announced at 8:00 a.m. Eastern time, conference call to begin at 8:30 a.m.

IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer
globenewswire.com24 June 2024 Sentiment: POSITIVE

Novel IL-12 Immunotherapy Administered with Standard of Care as First-Line Treatment Expects topline results by the end of July LAWRENCEVILLE, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in advanced development of its non-viral DNA-mediated immunotherapy, announces database lock for its Phase 2 OVATION 2 Study evaluating the safety and efficacy of IMNN-001 in patients with advanced ovarian cancer.

IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024
GlobeNewsWire21 March 2024 Sentiment: NEGATIVE

LAWRENCEVILLE, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 10:00 a.m. ET on Thursday, March 28, 2024 to discuss financial results for the year ended December 31, 2023 and provide an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of first-line, locally advanced-stage ovarian cancer, and on its PlaCCine modality, a proprietary mono- or multi-cistronic DNA plasmid and a synthetic DNA delivery technology for the expression of pathogen antigens in preclinical studies for the development of next-generation vaccines.

What type of business is Imunon?

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

What sector is Imunon in?

Imunon is in the Healthcare sector

What industry is Imunon in?

Imunon is in the Biotechnology industry

What country is Imunon from?

Imunon is headquartered in United States

When did Imunon go public?

Imunon initial public offering (IPO) was on 01 March 1999

What is Imunon website?

https://imunon.com

Is Imunon in the S&P 500?

No, Imunon is not included in the S&P 500 index

Is Imunon in the NASDAQ 100?

No, Imunon is not included in the NASDAQ 100 index

Is Imunon in the Dow Jones?

No, Imunon is not included in the Dow Jones index

When was Imunon the previous earnings report?

No data

When does Imunon earnings report?

The next expected earnings date for Imunon is 28 March 2025